198 related articles for article (PubMed ID: 28143881)
1. Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients.
Pria AD; Pinato D; Roe J; Naresh K; Nelson M; Bower M
Blood; 2017 Apr; 129(15):2143-2147. PubMed ID: 28143881
[TBL] [Abstract][Full Text] [Related]
2. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease.
Uldrick TS; Polizzotto MN; Aleman K; Wyvill KM; Marshall V; Whitby D; Wang V; Pittaluga S; O'Mahony D; Steinberg SM; Little RF; Yarchoan R
Blood; 2014 Dec; 124(24):3544-52. PubMed ID: 25331113
[TBL] [Abstract][Full Text] [Related]
3. Castleman disease in pediatrics: Insights on presentation, treatment, and outcomes from a two-site retrospective cohort study.
Sopfe J; Endres A; Campbell K; Hayes K; Trout AT; Liang X; Lorsbach R; O'Brien MM; Cost CR
Pediatr Blood Cancer; 2019 May; 66(5):e27613. PubMed ID: 30680887
[TBL] [Abstract][Full Text] [Related]
4. Higher rate of progression in HIV- than in HIV+ patients after rituximab for HHV8+ multicentric Castleman disease.
Rasmussen C; Gérard L; Fadlallah J; Corvilain E; Galicier L; Meignin V; Oksenhendler E; Boutboul D
Blood Adv; 2023 Sep; 7(18):5663-5669. PubMed ID: 37288720
[TBL] [Abstract][Full Text] [Related]
5. Human Herpesvirus Type 8-positive Multicentric Castleman Disease.
Melikyan AL; Egorova EK; Julhakyan HL; Kovrigina AL; Savchenko VG
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S159-65. PubMed ID: 27133959
[TBL] [Abstract][Full Text] [Related]
6. Successful rituximab treatment of an elderly Japanese patient with HHV8-positive, HIV-negative multicentric Castleman disease.
Kaga H; Kurahashi H; Kubota A; Hatano Y; Nanjo H; Wakui H; Takahashi N
Int J Hematol; 2022 Jan; 115(1):129-134. PubMed ID: 34591291
[TBL] [Abstract][Full Text] [Related]
7. Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease.
Hoffmann C; Schmid H; Müller M; Teutsch C; van Lunzen J; Esser S; Wolf T; Wyen C; Sabranski M; Horst HA; Reuter S; Vogel M; Jäger H; Bogner J; Arasteh K
Blood; 2011 Sep; 118(13):3499-503. PubMed ID: 21778341
[TBL] [Abstract][Full Text] [Related]
8. Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman disease.
Stebbing J; Adams C; Sanitt A; Mletzko S; Nelson M; Gazzard B; Newsom-Davis T; Bower M
Blood; 2011 Jul; 118(2):271-5. PubMed ID: 21511959
[TBL] [Abstract][Full Text] [Related]
9. HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma.
Nicoli P; Familiari U; Bosa M; Allice T; Mete F; Morotti A; Cilloni D; Saglio G; Guerrasio A
Int J Hematol; 2009 Oct; 90(3):392-396. PubMed ID: 19756920
[TBL] [Abstract][Full Text] [Related]
10. Overview of Castleman disease.
Dispenzieri A; Fajgenbaum DC
Blood; 2020 Apr; 135(16):1353-1364. PubMed ID: 32106302
[TBL] [Abstract][Full Text] [Related]
11. Concurrent HIV viral blips during two episodes of multicentric Castleman disease in an adult on antiretroviral therapy: Implication for HIV persistence.
Darwish I; Costiniuk C; Kronfli N; Haegert D; Routy JP
IDCases; 2021; 26():e01315. PubMed ID: 34786336
[TBL] [Abstract][Full Text] [Related]
12. Brief communication: rituximab in HIV-associated multicentric Castleman disease.
Bower M; Powles T; Williams S; Davis TN; Atkins M; Montoto S; Orkin C; Webb A; Fisher M; Nelson M; Gazzard B; Stebbing J; Kelleher P
Ann Intern Med; 2007 Dec; 147(12):836-9. PubMed ID: 18087054
[TBL] [Abstract][Full Text] [Related]
13. Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases.
Nagao A; Nakazawa S; Hanabusa H
J Hematol Oncol; 2014 Jan; 7():10. PubMed ID: 24438824
[TBL] [Abstract][Full Text] [Related]
14. Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease.
Gérard L; Michot JM; Burcheri S; Fieschi C; Longuet P; Delcey V; Meignin V; Agbalika F; Chevret S; Oksenhendler E; Galicier L
Blood; 2012 Mar; 119(10):2228-33. PubMed ID: 22223822
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: A systematic review.
Rehman MEU; Chattaraj A; Neupane K; Rafae A; Saeed S; Basit J; Ibrahim A; Khouri J; Mukherjee S; Anwer F
Eur J Haematol; 2022 Oct; 109(4):309-320. PubMed ID: 35770616
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases.
Ramaswami R; Lurain K; Polizzotto MN; Ekwede I; Waldon K; Steinberg SM; Mangusan R; Widell A; Rupert A; George J; Gonçalves PH; Marshall VA; Whitby D; Wang HW; Pittaluga S; Jaffe ES; Little RF; Uldrick TS; Yarchoan R
Blood Adv; 2021 Mar; 5(6):1660-1670. PubMed ID: 33720337
[TBL] [Abstract][Full Text] [Related]
17. Human herpesvirus 8-positive multicentric Castleman disease with germinotropic plasmablastic aggregates: Overlapping spectrum of human herpesvirus 8-associated lymphoproliferative disorder.
Nakaya Y; Ishii N; Kasamatsu Y; Shimizu K; Tatsumi N; Tsutsumi M; Yoshida M; Yoshimura T; Hayashi Y; Nakao T; Inoue T; Yamane T
Pathol Int; 2020 Aug; 70(8):574-580. PubMed ID: 32449234
[TBL] [Abstract][Full Text] [Related]
18. Human immunodeficiency virus-associated multicentric Castleman disease refractory to antiretroviral therapy: clinical features, treatment and outcome.
Alzahrani M; Hull MC; Sherlock C; Griswold D; Leger CS; Leitch HA
Leuk Lymphoma; 2015 May; 56(5):1246-51. PubMed ID: 25093377
[TBL] [Abstract][Full Text] [Related]
19. Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease.
Powles T; Stebbing J; Montoto S; Nelson M; Gazzard B; Orkin C; Webb A; Bower M
Blood; 2007 Dec; 110(12):4132-3. PubMed ID: 18024800
[No Abstract] [Full Text] [Related]
20. HIV-associated multicentric Castleman disease.
Reddy D; Mitsuyasu R
Curr Opin Oncol; 2011 Sep; 23(5):475-81. PubMed ID: 21760504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
